Women’s Health Therapeutics Market

Women’s Health Therapeutics Market Outlook 2031

The global women’s health therapeutics market size was valued at USD 179.14 Billion in 2022 and is projected to reach USD 382.69 Billion by 2031, expanding at a substantial CAGR of 8.8.% during the forecast period, 2023–2031. The growth of the market is attributed to the growing prevalence of chronic disease, increasing expenditure on healthcare, lifestyle-associated disorders, launch of novel and effective drugs, and complications related to pregnancy.

In healthcare sector, women health therapeutics market is leading because every woman deals with some type of gynecological disorder at some point in her entire life. Women’s health therapeutics comprises of extensive range of treatment by using several devices and drugs for different health disorders in women.

Get Free Sample Report

Various advanced technologies are present for the treatment of women’s health disorders includes ovarian-related problems, cancer, and urological disorders. Many gynecological diseases are cured with proper treatment but in some cases, they can be fatal if diagnosed at right time. Currently, there is pipeline of molecules such as AZD4901, romosozumab (AMG785), abaloparatide, elagolix, ASP1707, vaginorm and teriparatide.

The increasing cases of infertility is projected to push the market. Based on World Health Organization (WHO), infertility in women is serious disability with 5th highest rank across globe, because of this requirement of infertility therapeutics is increasing. According to Centers for Disease Control and Prevention (CDC), around 12% of women have taken any kind of infertility services in their life.

Increasing awareness about cancer, infections, menopause, and osteoporosis is projected to aid the market of women’s health. Furthermore, launch of novel drug therapies by key market players helps for the expansion of the market. In March 2017, TESARO, Inc. received approval for Zejula from the U.S. Food and Drug Administration (FDA). This drug is used for advanced ovarian cancer treatment.

In South Africa, the WHO released guidelines for people living with HIV, to get diagnosis immediately using Antiretroviral Therapy (ART). This recommendation is called as Test and Treat Policy for HIV. Private companies and governments are rising their expenditure on improvement of women’s healthcare particularly for ovarian, cervical, uterine, and breast cancers. Mergers and acquisitions, product approvals, collaborations, and funding are serving the market.

Women’s Health Therapeutics Market Trends, Drivers, Restraints, and Opportunities

• Growing prevalence of several health conditions and disorders among women is projected to boost the market growth over the forecast period.
• Rising awareness about various drugs treatments among people and increasing production of advanced therapeutic devices are anticipated to drive the market expansion in the coming years.
• Technological advancement is major factor that is expected to drive the expansion of the market.
• Increasing government investments on infrastructure of healthcare and growing adoption of women’s health programs are estimated to fuel the expansion of the market.
• Growing cases of infertility and rising incidences of chronic disorders are expected to push the growth of the market over the forecast period.
• Increasing investment in research and development by major market players is one of the factor responsible for pushing the market growth in the coming years.
• High cost of therapeutic treatment and side effects of drugs are major factor responsible for hampering the market growth over the forecast period.

Scope of Women’s Health Therapeutics Market Report

The report on the global women’s health therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Women’s Health Therapeutics Market Segment Insights

Type Segment Analysis

Based on types, the women’s health therapeutics market is divided into infection, pregnancy, and oncology. The oncology segment is further sub-divided into cervical cancer, vaginal & vulvar cancer, uterine cancer, and ovarian cancer. The oncology segment is expected to hold a key share of the market during the forecast period.

The cervical cancer is most common type of oncology which held a majority of the revenue share. Novel launch of products, ease reimbursement for better and effective treatment, several product approvals, and rising clinical trials are major factor responsible for propelling the segment growth. In June 2018, the FDA approved Merck and Co. for its KEYTRUDA drug. This drug is used for treating cervical cancer

However, the infection segment is anticipated to expand at a rapid pace during the forecast period due to growing prevalence of tuberculosis (TB), toxoplasmosis, bacterial vaginosis (BV), cytomegalovirus, herpes simplex virus, urinary tract infection (UTI), and hepatitis A, B, C, D, and E. As per Centers for Disease Control and Prevention (CDC), in the U.S., BV is the most dominant infection in women. Also, every year around 21 million women between ages 14 to 49 get affected by BV.

Get Free Sample Report

Regional Outlook

On the basis of regions, the women’s health therapeutics market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increased funding, growing cases of chronic diseases, and rising mergers and acquisitions.

Based on the Connecticut Small Business Development Center, in 2015, GestVision, Inc., was funded of USD 2 million for diagnostic test of preeclampsia of women who were pregnant. Quest Therapeutics acquired two hospitals, namely, the Hospital of Central Connecticut and the William W. Backus Hospital, of Hartford HealthCare (HHC) in September 2017. This acquisition helped physicians and patients for timely treatment and care by accessing testing services.

On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rising per capita revenue, increasing aging population, growing prevalence of chronic diseases, and increasing product approvals. The China Food and Drug Administration approves Triumeq in January 2018. Triumeq is manufactured by GlaxoSmithKline (GSK). It is single pill and low cost treatment for Human Immunodeficiency Virus (HIV).

Get Free Sample Report

Segments

The global women’s health therapeutics market has been segmented on the basis of

Types

• Infection
• Pregnancy
• Oncology
  • Cervical Cancer
  • Ovarian Cancer
  • Uterine Cancer
  • Vaginal & Vulvar Cancer

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Bayer AG
• Pfizer, Inc.
• Teva Pharmaceutical
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Novartis International AG
• Abbott Laboratories
• Eli Lilly and Company
• Merck & Co., Inc.
• Novo Nordisk A/S
• Lupin Pharmaceuticals Inc.
• Blairex Laboratories Inc.
• Amgen Inc.

Competitive Landscape

Key players competing in the women’s health therapeutics market include Bayer AG; Pfizer, Inc.; Teva Pharmaceutical; F. Hoffmann-La Roche Ltd.; Johnson & Johnson Services Inc.; Novartis International AG; Abbott Laboratories; Eli Lilly and Company; Merck & Co., Inc.; Novo Nordisk A/S; Lupin Pharmaceuticals Inc.; Blairex Laboratories Inc.; and Amgen Inc.

Major market players are adopting several market strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.